Fulcrum Therapeutics (FULC)
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Summit Plc (SMMT)
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
United Therapeutics Corporation (UTHR)
UTHR: Notification
Johnson & Johnson (JNJ)
Johnson & Johnson - Johnson & Johnsons INLEXZO™(gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
Johnson & Johnson (JNJ)
Johnson & Johnsons INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
Spyre Therapeutics (SYRE)
Spyre Therapeutics Announces Grants of Inducement Awards
Taysha Gene Therapies (TSHA)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Meihua International Medical Technologies Co Ltd (MHUA)
Meihua International Medical Technologies Co., Ltd. Received Nasdaq Delisting Notice
Vera Therapeutics Inc. (VERA)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma (NAMS)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)